Achieve Life Sciences Inc (OQ:ACHV)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 22722 29TH DR. SE, SUITE 100
SEATTLE WA 98021
Tel: 1-404-736-3838
Website: achievelifesciences.com
IR: See website
<
Key People
Richard Stewart
Executive Chairman of the Board
Cindy Jacobs
President, Director, Chief Medical Officer
John A. Bencich
Chief Executive Officer, Director
Jerry Wan
Principal Accounting Officer
   
Business Overview
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company engaged in the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence. The Company's product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over-the-counter (OTC) products.
Financial Overview
For the nine months ended 30 September 2023, Achieve Life Sciences Inc revenues was not reported. Net loss decreased 22% to $24.3M. Lower net loss reflects Research & Development decrease of 39% to $12.5M (expense), Interest income increase from $81K to $617K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.23 to -$1.27.
Employees: 20 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $151.09M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$33.36M as of Sep 30, 2023
Net annual income (TTM): -$35.57M as of Sep 30, 2023
Free cash flow (TTM): -$31.26M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 34,251,911 as of Feb 28, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.